RCS - Arecor Therapeutics - Upcoming conference attendance

Arecor TherapeuticsAnnouncement

18/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260518:nRSR5499Ea&default-theme=true

RNS Number : 5499E  Arecor Therapeutics PLC  15 May 2026

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Upcoming conference attendance

Cambridge, UK, 18 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical
stage biotech company developing superior therapeutics that can reduce
treatment burden and improve outcomes for people living with diabetes, obesity
and other cardiometabolic diseases, will be attending the American Diabetes
Association (ADA) 2026 Scientific Sessions and the BIO International
Convention in San Diego.

 

American Diabetes Association (ADA) 2026 Scientific Sessions - 5-8 June 2026,
New Orleans

Arecor's CEO, Dr Sarah Howell, and CSO, Dr Jan Jezek, will be attending ADA
alongside over 12,000 leaders in the diabetes field, to meet with KOLs,
researchers and investors.  ADA is the largest meeting in the field of
diabetes care, providing a platform for the latest advancements in technology
and innovative treatments, including Arecor's lead clinical stage product,
AT278.  AT278 is the only ultra-concentrated, ultra-rapid acting insulin
designed to accelerate the advancement of the next generation of Automated
Insulin Delivery Systems.

 

BIO International Convention - 22-25 June 2026, San Diego

Jalini Gugagayanan, Business Development Manager at Arecor, will be attending
the BIO International Convention, to meet potential partners and industry
contacts at the largest and most comprehensive event for biotechnology, with
over 20,000 industry leaders from around the world in attendance.

 

For attendees at either conference interested in meeting the Arecor team,
please email BD@arecor.com.

-ENDS-

For more information, please contact:

 

 Arecor Therapeutics plc                          +44 (0) 1223 426060

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer            info@arecor.com

 Singer Capital Markets Advisory LLP              +44 (0) 20 7496 3000

(NOMAD and Broker)
 Phil Davies, James Fischer

 Vigo Consulting (Financial Communications)       +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                  arecor@vigoconsulting.com

 Vida Strategic Partners (US Investor Relations)  +1 (415) 675-7401

 Stephanie Diaz                                   sdiaz@vidasp.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a clinical stage biotech company developing
superior therapeutics that can reduce treatment burden and improve outcomes
for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid
acting insulin, which enables disruptive drug delivery devices. It is being
co-developed with Sequel Med Tech, a company commercialising state-of-the art
insulin delivery devices. Arecor is also developing a novel oral delivery
platform for peptides with its first validation target a GLP-1 receptor
agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For
further details please see www.arecor.com (http://www.arecor.com/)

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to
accelerate the absorption of insulin post injection even at very high
concentrations (500U/mL). With its best-in-class profile, it has the potential
to disrupt the market for insulin treatment as the first concentrated, yet
very rapid acting insulin for the growing population of people with diabetes
with high daily insulin needs as well as to act as a critical enabler in the
development of next-generation, miniaturised longer wear automated insulin
delivery (AID) systems.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEANSSFDEKEEA



            Copyright 2019 Regulatory News Service, all rights reserved